Trial
NCT04629781
Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Swiss Cancer Institute
Collaborators
—
Condition
Metastatic Castration-resistant Prostate Cancer
Intervention
Docetaxel micellar
Why stopped
SAKK decided to premature terminate this trial as additional follow-up visits do not further contribute to the efficacy data. This decision does not adversely impact the patients.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-01